Methadone: Substitution Therapy and Pain Management

Methadone (brand names including L Polamidon, Methaddict and generic solutions) is a synthetic opioid and a full agonist at the μ opioid receptor. In Germany, methadone is primarily used in substitution treatment for opioid dependence. It is also an important component of specialized pain therapy, especially for chronic pain with complex medical history or for refractory cancer pain. Methadone is offered in Germany as a racemate or as levomethadone, with levomethadone being the levorotatory form that is analgesically and substitutionally effective and works comparably at lower doses.

Methadone is demanding compared to short-acting opioids because of its long and variable half-life. The initial phase of therapy is the most critical because the drug level builds up over days. Too rapid dose escalation leads to accumulation and increases the risk of respiratory depression with potentially fatal consequences. Therefore, methadone should only be prescribed by experienced physicians with specialization in addiction medicine or pain medicine.

Mechanism of Action

As a full μ agonist, methadone activates opioidergic pain modulation at the spinal and supraspinal level. Unlike pure μ agonists, methadone also has antagonistic activity at the NMDA receptor. This NMDA component is clinically significant because it can slow tolerance development and better address neuropathic pain components. Additionally, methadone moderately inhibits the reuptake of serotonin and noradrenaline.

The half-life is 15 to 60 hours and highly variable between individuals. Steady state is only achieved after three to seven days. Metabolism occurs primarily hepatically via CYP3A4, to a lesser extent via CYP2B6 and CYP2D6. Genetic variants and concomitant medications significantly influence plasma levels, which complicates predictability. Plasma protein binding is high (approximately 85 to 90 percent), and tissue distribution is pronounced.

Clinically relevant is the dose-dependent prolongation of QT interval. Methadone blocks the hERG potassium channel on the myocardium, which can trigger Torsade de Pointes in patients with risk factors (electrolyte disturbances, other QT prolonging medications, congenital syndromes). ECG monitoring is part of safe therapy management, especially at doses above 100 mg per day.

Areas of Use

• Substitution treatment for opioid dependence, long-term experience, good stabilization of social and health status
• Severe chronic pain, especially when other strong opioids fail or when neuropathic components are present
• Cancer pain in specialized palliative medicine, often as a rotation option after tolerance or side effects from other opioids
• Treatment of opioid-induced hyperalgesia after interdisciplinary indication assessment

Due to its pharmacokinetic complexity, methadone is not considered a first-line treatment in acute pain therapy or in the postoperative setting, where more easily controllable opioids such as morphine or oxycodone are standard.

Dosage and Administration

Substitution Adults: Start with 10 to 30 mg methadone racemate or 5 to 15 mg levomethadone orally, followed by careful titration in the first few days in 5 to 10 mg increments under medical supervision. Maintenance dose individually 60 to 120 mg per day, in individual cases higher.

Pain therapy: Equianalgesic conversion is not linear. When switching from high-dose morphine to methadone, the methadone dose must be reduced nonlinearly because the NMDA antagonistic effect disproportionately increases drug potency. The switch should be made by experienced pain specialists using standardized protocols.

Administration: In substitution treatment as a solution for once-daily administration under supervision, in pain therapy usually divided into two to three daily doses. Methadone is a controlled substance in Germany and is prescribed on a special prescription form.

Renal insufficiency: Methadone is one of the preferred opioids in renal insufficiency since it is metabolized primarily hepatically. Hepatic insufficiency: In severe impairment, level monitoring and individualized dosing. Elderly patients: Halve starting dose, slower titration, ECG before therapy initiation.

Side Effects

Very common: Constipation, fatigue, nausea, sweating, dry mouth, dizziness, headaches.

Common: Vomiting, sleep disturbances or conversely daytime drowsiness, weight gain, loss of libido, erectile dysfunction, menstrual irregularities, edema, loss of appetite.

Cardiac: QT prolongation with risk of Torsade de Pointes, especially at doses above 100 mg per day, with hypokalemia, hypomagnesemia or concurrent use of other QT prolonging substances.

Respiratory: Respiratory depression with too rapid dose escalation, significantly increased with additional CNS depressants (benzodiazepines, alcohol, pregabalin) or in patients with sleep apnea.

Endocrine: Secondary hypogonadism, hyperprolactinemia, changes in cortisol secretion. With long-term therapy, laboratory monitoring and symptom surveillance are advisable.

Drug Interactions

• CYP3A4 inhibitors (Itraconazole, Ketoconazole, Erythromycin, Clarithromycin, Ritonavir, Grapefruit juice): elevated methadone levels, increased respiratory depression and QT risk.
• CYP3A4 inducers (Rifampicin, Phenytoin, Carbamazepine, Efavirenz, St. John's Wort): reduced levels, risk of underdosing with withdrawal symptoms.
• QT prolonging agents (Amiodarone, Sotalol, some antibiotics such as Erythromycin and Clarithromycin, Azole antifungals, Citalopram at higher doses): cumulative QT prolongation with arrhythmia risk.
• Benzodiazepines, Z substances, Alcohol, Pregabalin, Gabapentin: Enhanced central depression and respiratory depression.
• SSRI, SNRI, MAO inhibitors, Tricyclics, Linezolid, Tramadol, Methylene blue: Risk of serotonin syndrome.
• Naloxone, Naltrexone: Reversal of methadone effect with acute withdrawal.
• Diuretics, Glucocorticoids: Hypokalemia and hypomagnesemia as risk enhancers for Torsade de Pointes.

Special Notes

Pregnancy: Substitution should be continued, withdrawal attempts during pregnancy are potentially dangerous. Birth and postpartum period are ideally managed at a specialized clinic, and the newborn is monitored for neonatal abstinence syndrome. Breastfeeding: Transfer into breast milk in small amounts, breastfeeding under stable substitution is usually possible, individual counseling with pediatrics.

Children: Pain therapy only in specialized centers of pediatric oncology and palliative medicine.

ECG: Before initiation and during therapy regularly, especially at doses above 100 mg per day or with risk factors. With QTc above 500 ms, therapy adjustment must be urgently reviewed, safety-relevant hypokalemia and hypomagnesemia should be corrected.

Sleep apnea and COPD: Caution advised, respiratory testing and possibly polysomnography are advisable. Minimize concomitant medication with other respiratory depressants.

Driving ability: During the titration phase and with dose changes to be individually assessed, often preserved with stable substitution.

Storage: Methadone is highly potent and even small amounts can be life-threatening in opioid naive persons, especially in children. Safe storage in a lockable container is mandatory.

You might also be interested in

• Buprenorphine, partial μ agonist with ceiling effect
• Morphine, gold standard of strong opioids
• Oxycodone, semi-synthetic strong opioid
• Tapentadol, μ agonist with additional noradrenaline reuptake inhibition
• Sufentanil, highly potent opioid in anesthesia

Frequently Asked Questions

Sources

• Gelbe Liste, Methadone Drug Profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, Guidelines on Substitution Treatment for Opioid Dependence
• EMA, European Medicines Agency